Posted: Wednesday, March 22, 2023
Bing Chen, PhD, of the Affiliated Drum Tower Hospital of Nanjing University Medical School, China, and colleagues aimed to pinpoint potential prognostic biomarkers of multiple myeloma to construct a predictive model of pyroptosis-related genes. According to the investigators, their model may provide insight for follow-up studies and aid in the development of novel risk stratification for multiple myeloma. The results of this study were published in BMC Medical Genomics.
“We identified nine pyroptosis-related genes as prognostic markers for multiple myeloma and constructed a prognostic predictive model with high predictive performance,” the study authors concluded. “This model can enhance the predictive ability of International Staging System staging and give a reference for clinical decision-making.”
The Cancer Genome Atlas and Gene Expression Omnibus databases were queried for sequencing and clinical data of CD138-positive myeloma cells within bone marrow from 764 patients. Molecular subtype screening was identified using non-negative matrix factorization, and patients were stratified by risk group for Kaplan-Meier survival curves.
From The Cancer Genome Atlas database, 33 pyroptosis-related genes were extracted, in which 4 molecular subtypes of multiple myeloma were defined. Of note, patients in the first of four clusters identified demonstrated poorer survival than those in the second cluster (P = .035).
Patients who were classified as high risk had a significantly worse survival compared with those in the low-risk group (P < .001), and this was verified by the GSE2658 validation data set. Furthermore, the best prognostic predictive performance was shown by the nomogram constructed by gender, age, risk score, and International Staging System stage, yielding a consistency index of 0.721.
Disclosure: The study authors reported no conflicts of interest.